IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Hrair Kirakossian et al.

APPLICATION NO.: 10/765,773

FILING DATE: January 26, 2004

TITLE: Biomarkers Detection in Circulating Cells

EXAMINER: Pensee T. Do

GROUP ART UNIT: 1641

ATTY, DKT, NO.: 25237-12891

CERTIFICATE OF ELECTRONIC (EFS-WEB) TRANSMISSION

I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with 37 C.F.R. § 1.8(a)(i)(C) from the Pacific Time Zone of the United States on the local date shown below.

Dated: August 8, 2008 ______ By: /Narinder Banait/ _____ Narinder S, Banait, Red, No. 43.482

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

within three months of the filing date of the application, or date of entry
into the national stage of an international application, or before the mailing
date of a first office action on the merits, whichever event last occurred:

Ш	before the mailing of a first official action after the filing of a request for					
	mination (RCE) under 37 CFR § 1.114;					
after three months of the filing date of this national application or						
of entry of the national stage in an international application, or after						
	mailing date o	f the first official action on the merits, whichever event last				
	occurred, but l	before the mailing date of the first to occur of either: (1) a				
	final action un	der 37 CFR §1.113; or (2) an action that otherwise closes				
	prosecution in the application, and:					
attached hereto is the fee set forth under 37 CFR §1.17(
	submi	bmission of this Information Disclosure Statement under 37				
	CFR.	R.§ 1.97(c); OR				
	☐ Appli	cant certifies pursuant to 37 CFR § 1.97(e) that:				
		each item of information contained in this Information				
		Disclosure Statement was first cited in a communication				
		from a foreign patent office in a counterpart foreign				
		application not more than three months prior to the filing of				
		this Statement; OR				
		no item of information contained in this Information				
		Disclosure Statement was cited in a communication from a				
		foreign patent office in a counterpart foreign application				
		and, to the knowledge of the person signing this				
		certification after making reasonable inquiry, no item of				
		information contained in this Statement was known to any				
		individual designated under 37 CFR § 1.56(c) more than				
		three months prior to the filing of this Statement;				
\boxtimes	on or before t	the payment of the issue fee but after the mailing date of the				
	first to occur of either: (1) a final action under 37 CFR § 1.113; (2) a					
	notice of allowance under 37 CFR § 1.311; or (3) an action that otherwise					
	closes prosecution in the application, and:					
		cant certifies pursuant to 37 CFR. § 1.97(e) that:				
		each item of information contained in this Information				
		Disclosure Statement was cited in a communication from a				
		foreign patent office in a counterpart foreign application				
		not more than three months prior to the filing of this				
		Statement;				

				\boxtimes	no item of information contained in this Information			
					Disclosure Statement was cited in a communication from a			
					foreign patent office in a counterpart foreign application			
					and, to the knowledge of the person signing this			
					certification after making reasonable inquiry, no item of			
					information contained in this Statement was known to any			
					individual designated under 37 CFR § 1.56(c) more than			
					three months prior to the filing of this Statement; AND			
			\boxtimes	attache	d hereto is the fee set forth under 37 CFR §1.17(p) for			
				submis	sion of this Information Disclosure Statement under 37			
				CFR.§	1.97(d); OR			
			after th	he paym	ent of the issue fee. Applicant requests that the information			
			contai	ned in th	is Information Disclosure Statement be placed in the file			
	according to 37 CFR § 1.97(i), although the information may not be							
considered by the USPTO.					the USPTO.			
☐ This application relies, ur				on relies	s, under 35 U.S.C. § 120, on the earlier filing date of prior			
		application No, filed on, and the references cited therein are hereby referenced, but are not required to be provided in this application under 37 CFR \S 1.98(d).						
		Each i	ach item of information contained in this Information Disclosure Statement was					
		cited i	cited in a communication from a foreign patent office in a counterpart application,					
		and th	e comm	nmunication was not received by any individual designated in 37 CFR				
		§ 1.56(c) more than thirty days prior to the filing of this Information Disclosure						
		Staten	1.704(d).					
					Respectfully submitted,			
					HRAIR KIRAKOSSIAN ET AL.			
Dated:	_Aug	ust_8, 20	008		By: /Narinder Banait/			
					Fenwick & West LLP			
					Silicon Valley Center			
					801 California Street			
					Mountain View, CA 94041 Tel.: (650) 335-7818			
					Fax.: (650) 938-5200			